DISCOVER BIOMÉRIEUX SOLUTION FROM PREVENTION TO DETECTION
World Meningitis Day
Meningitis is a devastating disease with a high case fatality rate1 and leading to serious long-term complications. Meningitis remains a major global public-health challenge. Epidemics of meningitis are seen across the world.
Many organisms can cause meningitis including bacteria, viruses, fungi, and parasites. Bacterial meningitis is of particular concern. Around 1 in 6 people who get this type of meningitis die and 1 in 5 have severe complications2. Distinguishing viral from bacterial meningitis based on clinical presentation is challenging. Patients often present with similar symptoms and bacterial meningitis can be fatal in 24 to 48 hours3.
bioMérieux has an offer to meet the challenges of meningitis enabling timely prevention and accurate diagnosis:
PREVENTING GBS
Streptococcus agalactiae or Group B Streptococcus (GBS) has long been a leading cause of neonatal infection, including sepsis, pneumonia, and meningitis. To prevent GBS neonatal infections, the ASM Guidelines for the Detection and Identification of Group B Streptococcus4 recommends a universal screening at the 36/37 weeks of pregnancy.
CHROMID® Strepto B has been validated to detect hemolytic and non-hemolytic GBS from recto vaginal samples of pregnant women.
In the new Guidelines for the Detection and Identification of Group B Streptococcus, the ASM mentions the CHROMID® Strepto B as medium for GBS detection. After an enrichment step, in 18-24 hours of incubation, CHROMID® Strepto B provides: Selective and chromogenic isolation for the screening of group B streptococci (S. agalactiae) Detection of hemolytic and non-hemolytic GBS Excellent performance for GBS prenatal screening in terms of nutrient capacity and sensitivity of detection Compatible with PhenoMATRIX® and WASPLab® automated systems.
TARGETED DIAGNOSIS
ARGENE®
HSV1&2 VZV R-GENE® HSV1 HSV2 R-GENE® VZV R-GENE®
ARGENE® provides ready-to-use PCR kits for the detection of pathogens responsible for viral meningitis. Kits are designed for use on the most common open platforms, allowing the ability to run one single sample or to process batch analysis.
SYNDROMIC MOLECULAR TESTING
BIOFIRE® FILMARRAY® Meningitis/Encephalitis (ME) Panel
1 Test. 14 Targets. ~1 Hour.
When it comes to meningitis, every minute counts because bacterial meningitis can prove fatal within 24-48 hours for otherwise healthy people5. Timely optimal treatment depends on quick identification of the pathogen as bacterial, viral or yeast.
The BIOFIRE ME Panel identifies 14 of the most common targets of Meningitis/Encephalitis with results in about an hour. The BIOFIRE ME Panel provides comprehensive results in a clinically actionable timeframe.
1 WHO - Defeating Meningitis by 2030, a global roadmap https://www.who.int/initiatives/defeating-meningitis-by-2030
2 https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed 9/7/2023
3 https://www.comomeningitis.org/facts. Accessed 9/7/2023
4 https://asm.org/Guideline/Guidelines-for-the-Detection-and-Identification-of-Group-B-Streptococcus
5 Confederation of Meningitis Organisations. Facts. www.comomeningitis.org/facts. Accessed 9/7/2023
Product Availability varies by country. Consult your local bioMérieux representative.
